AGPU AGPU Drug Discovery Services — Segment Reporting Other Item Amount

Other segment segments

Similar metrics at other companies

FSISegment Reporting Other Item Amount

$213.95K-42.1%

AMP

AMPHPharmaceutical Products — Segment Reporting Other Item Amount

$55.01M+40.1%

IRONOther Segment Items — Segment Reporting Other Item Amount

$6.02M+2.7%

HDSNSingle Reporting — Segment Reporting Other Item Amount

$2.06M+76.9%

LGNDDevelopment and Licensing of Biopharmaceutical Assets — Segment Reporting, Other Segment Item, Amount

$51.16M-29.0%

CYRXLife Sciences Services — Segment Reporting Other Item Amount

$4.04M+17.4%

Questions, answered.

What is AGPU's drug discovery services — segment reporting other item amount?

AGPU (AGPU) reported drug discovery services — segment reporting other item amount of $676.7K in Q4 2025.

How has AGPU's drug discovery services — segment reporting other item amount changed year-over-year?

AGPU's drug discovery services — segment reporting other item amount increased by 446768.0% year-over-year, from -$151.5 to $676.7K.

What does drug discovery services — segment reporting other item amount mean?

This metric captures miscellaneous income or expense items specific to the drug discovery services segment that do not fit into standard operating categories like cost of goods sold or research and development. It often includes non-recurring charges, unique adjustments, or minor operational items that are reported separately for segment transparency. Tracking this helps investors identify one-time events or unusual operational costs that could impact the segment's core profitability.